Apoptosis, a tightly controlled multi-step mechanism of cell death, is important for anti-cancer therapy-based elimination of tumor cells. However, this process is not always ecient. Small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC) cells display dierent susceptibility to undergo apoptosis induced by anticancer treatment. In contrast to SCLC, NSCLC cells are cross-resistant to a broad spectrum of apoptotic stimuli, including receptor stimulation, cytotoxic drugs and g-radiation. Since resistance of tumor cells to treatment often accounts for the failure of traditional forms of cancer therapy, in the present study attempts to ®nd a potent broad-range apoptosis inductor, which can kill therapy-resistant NSCLC cells were undertaken and the mechanism of apoptosis induction by this drug was investigated in detail. We found that staurosporine (STS) had cell killing eect on both types of lung carcinomas. Release of cytochrome c, activation of apical and eector caspases followed by cleavage of their nuclear substrates and morphological changes speci®c for apoptosis were observed in STS-treated cells. In contrast to treatment with radiation or chemotherapy drugs, STS induces mitochondrial dysfunction followed by translocation of AIF into the nuclei. These events preceded the activation of nuclear apoptosis. Thus, in lung carcinomas two cell death pathways, caspase-dependent and caspaseindependent, coexist. In NSCLC cells, where the caspase-dependent pathway is less ecient, the triggering of an AIF-mediated caspase-independent mechanism circumvents the resistance of these cells to treatment.
Introduction
The initial responsiveness of small cell lung carcinoma (SCLC) to anticancer drug and radiation treatment is in contrast with the relative resistance of non-small cell lung carcinoma (NSCLC) to the same types of intervention (Owens and Abelo, 1985; Joseph et al., 2000) . The reason for this dierence is not fully understood. Growing experimental evidences suggest that ionizing radiation as well as chemotherapy drugs trigger the intrinsic cellular death machinery in tumor cells (Zhivotovsky et al., 1999a) . If this is correct, one possible explanation for resistance of NSCLC to treatment is that SCLC and NSCLC cells have dierent susceptibility to undergo apoptosis. In many experimental models susceptibility to killing is related to the level of spontaneous apoptosis. In our previous study a higher level of spontaneous as well as radiation-and chemotherapy-induced apoptosis was detected in SCLC as compared with NSCLC lines (SirzeÂ n et al., 1998; Joseph et al., 1999 Joseph et al., , 2001 .
Apoptosis is a tightly controlled multi-step mechanism of cell death. One of the main roles in induction and execution of apoptosis belongs to the family of proteases, the caspases. This family of proteins consists of 14 members identi®ed at this day. Although overexpression of all known caspases confers cell killing via apoptosis, not all of them are normally involved in this process when constitutively expressed in cells (for review see Hengartner, 2000) . Recent studies demonstrate the ability of the two main initiator caspases (8 and 9) to signal via distinct pathways (receptor-or mitochondria-mediated, respectively) and activate the eector pro-caspase-3 within the cytosol (Hengartner, 2000) . In a previous study expression of pro-caspases in a panel of 16 SCLC and NSCLC cell lines was investigated. While pro-caspases-2, -3, -6, -7, and -9 were found in SCLC and NSCLC cells, pro-caspases-1, -4, and -10 were only expressed in NSCLC cells. The presence of pro-caspase-8 also seems to be limited to the NSCLC type, with the exception of one SCLC cell line, U1285, suggesting a de®ciency for several pro-caspases in SCLC cells (Joseph et al., 1999) . Investigation of the activation of the apoptotic signaling pathways in the SCLC and NSCLC cell lines was also performed using treatment with a broad spectrum of stimuli including receptor stimulation (aFas), treatment with a cytotoxic drug (etoposide: VP-16) and g-radiation (Joseph et al., 2001) . The SCLC cell lines were sensitive to ionizing radiation, VP16, and, depending on their pro-caspase-8 status, also to agonistic aFas treatment. This suggests that the presence of pro-caspase-8 does not appear to determine the sensitivity of SCLC cells to undergo radiation-or chemotherapy-triggered apoptosis (for details see Joseph et al., 2001) . The NSCLC cell lines were cross-resistant to all apoptotic stimuli used. Investigation of the components of the apoptotic machinery, however, revealed no signi®cant dierences in SCLC and NSCLC cells concerning the activation of apical caspase-8 (in particular in U1285) and -9, the subsequent activation of executioner caspases, such as caspase-3, or the release of cytochrome c into the cytosol after treatment with g-radiation or etoposide. Analysis of dierent biochemical hallmarks of nuclear apoptosis, however, indicated that the nuclear events (cleavage of PARP, DFF45/ICAD and DNA-PKcs, as well as DNA fragmentation) do not occur in the NSCLC cell lines even though caspase-3 was activated in these cells. Moreover, relocalization of active caspase-3 from cytosol into the nucleus was observed in the SCLC cells, but not in the NSCLC cells (Joseph et al., 2001) . Collectively, these data suggested that the inhibition of apoptosis in NSCLC cells occurs downstream of cytochrome c release and caspase activation and upstream of nuclear apoptotic event(s). It seems that an additional factor(s) might be required to kill NSCLC cells. Therefore, it is of importance to either identify the limiting factor(s) in order to supply/ suppress its function or to ®nd a type of treatment that can circumvent the inhibition of the apoptotic process. In any case the possibility of reactivation of the apoptotic execution machinery in NSCLC cells, which are resistant to spontaneous-and conventional anticancer treatment-induced-apoptosis will be of interest.
Search of potential broad-range apoptosis inductors revealed that staurosporine (STS) induces apoptosis in many types of cells, including various cancer cells (Caponigro et al., 1997; Jarvis and Grant, 1999; Gescher, 2000) . Although initially STS was designed as a protein kinase C inhibitor, nowadays it is clear that this compound is less speci®c and inhibits à cocktail' of kinases (Han et al., 2000) . The aim of the present study was to investigate if STS can kill both types of lung carcinomas, i.e. also the chemo-and radioresistant NSCLC type of lung cancer. If so, to identify the cell death pathway, which activation leads to the death of NSCLC cells. We found that STS was able to kill SCLC and NSCLC cell lines. Investigation of the apoptotic machinery showed in both cell types the release of cytochrome c, activation of the apicaland executioner-caspases, cleavage of nuclear substrates for caspases, and, ®nally, DNA fragmentation and morphological changes, speci®c for apoptosis.
Since the nuclear apoptotic events seem to be dependent on caspase activation, eect of the broadrange caspase inhibitor zVAD-fmk on STS-induced cell death was also analysed. Even if zVAD-fmk was able to inhibit caspase activities, and signi®cantly reduce PARP cleavage, it was unable to prevent STS-induced cell death in lung carcinomas, suggesting that a caspase-independent pathway also exists in these cells. We found that a mitochondrial transmembrane potential (DC m )-dependent release of the apoptosis inducing factor (AIF) into the cytosol and its relocalization into the nucleus occur in lung cancer cells upon STS treatment. These results indicated that in lung carcinomas two cell death pathways coexist. In the NSCLC type, where the caspase-dependent pathway is less ecient, dysfunction of mitochondria results in activation of an AIF-mediated caspase-independent pathway, which circumvent the resistance observed upon treatment with aFas, cytotoxic drugs and gradiation.
Results

Changes in nuclear morphology in SCLC and NSCLC cells after staurosporine treatment
Since in response to chemo-and radiation therapy morphological changes were not detected in NSCLC cells, we ®rst investigated whether any changes in morphology of these cells can be observed after treatment with STS. Cellular and nuclear morphology was analysed in U1810 NSCLC cells as well as in U1285 SCLC cells by MGG (May-GruÈ nwald Giemsa) and Hoechst 33342 staining, respectively. As shown in Figure 1 (compare A1, C1 with A2, C2), chromatin condensation, nuclear disintegration, vacuolization of the cytoplasm, all common features of apoptosis, were detected in cells treated with STS and stained with MGG. Furthermore, classical apoptotic condensation/ fragmentation of the nuclei was observed upon DNA staining with Hoechst ( Figure 1 , compare B1, D1 with B2, D2). Similar changes in nuclear morphology were observed in STS-treated pro-caspase-8-de®cient SCLC (H82) cells (data not shown). In situ nuclear DNA fragmentation was measured by using the TUNEL technique ( Figure 2A) . A TUNEL-positive fraction was detected in untreated U1285 and H82 SCLC cells ( Figure 2A1 and A3). Presence of these fractions re¯ected the amount of cells spontaneously undergoing apoptosis in SCLC cell lines, as previously described (Joseph et al., 1999 (Joseph et al., , 2001 . Untreated U1810 cells were TUNEL-negative ( Figure 2A5 ). The Jurkat T cells were used as a positive control in our experiments, since these cells positively responded to all types of treatment, including STS. As shown in Figure 2A7 and A8 there is a clear increase in the amount of TUNELpositive fraction at 24 h after treatment with STS. The two SCLC cell lines, U1285 and H82, revealed a large increase in the TUNEL-positive fraction 24 h after STS treatment ( Figure 2A2 and A4, respectively). STS-treated U1810 NSCLC cells presented a lower but statistically signi®cant increase in TUNEL staining as compared with the one observed in the SCLC cell lines at the same time point (24 h) ( Figure 2A6 vs A2 and A4).
Staurosporine does not induce cell cycle arrest in SCLC and NSCLC In order to delineate the possible contribution of cell cycle arrest in cell death induced by STS,¯ow cytometry analysis was performed ( Figure 2B ). Twenty-four hours post-treatment with STS both U1810 and H82 cells undergo apoptosis as documented by the appearance of a subG 1 peak. No major cell cycle perturbations were observed in these cells prior to the manifestation of hypoploidy. Similar results were obtained in STS-treated U1285 and Jurkat cells (data not shown). FACS analysis showed a higher sensitivity of the SCLC cells to undergo apoptosis as compared with the NSCLC cells, which is compatible with results obtained with the TUNEL technique ( Figure 2A ). The subG 1 peak in the H82 cell line was almost two times higher than in the U1810 cell line at the same time after STS treatment ( Figure 2B ).
Release of cytochrome c upon staurosporine treatment of SCLC and NSCLC Mitochondria play an important role in the regulation of apoptosis. Speci®cally the release of several proteins, normally located in the intermembrane space of mitochondria, has been observed during the early stages of apoptotic cell death (Hengartner, 2000) . Among these proteins is cytochrome c, which after being released into the cytosol interacts with Apaf-1 and in presence of dATP stimulates activation of procaspase-9 and thereby triggers the execution phase of apoptosis. Thus, dierences in the regulation of cytochrome c release from mitochondria might explain the dierence in sensitivity of SCLC and NSCLC cells to treatment with anticancer drugs. Therefore the appearance of cytochrome c in cytosol was analysed in STS-treated cells. The presence of a 12-kDa polypeptide corresponding to cytochrome c was detected by Western blot technique in cytosolic extracts 6 h after STS treatment in all SCLC and NSCLC cell lines tested as well as in Jurkat cells (Figure 3 ). These data were con®rmed by confocal microscopy. The punctate cytoplasmic staining with Abs against cytochrome c, which is related to the mitochondrial localization of this protein, becomes considerably more diuse after treatment of cells with STS (data not shown).
Activation of apical caspases-8 and -9 after staurosporine treatment occurs in SCLC and NSCLC Recently we have shown that SCLC and NSCLC cell lines dier in the expression of pro-caspase-8. Whereas expression of this pro-enzyme was observed in all NSCLC cell lines tested, no expression was detected in Figure 1 Cells (MGG staining) and nuclear (Hoechst 33258 staining) apoptotic morphology upon staurosporine treatment of SCLC and NSCLC cells. Cells incubated with 1 mM STS for 24 h (2) were compared with untreated cells (1). Cells were pretreated with the caspase inhibitor zVAD-fmk (20 mM) for 1 h before STS addition (3). Morphological changes in U1285 and U1810 cells were analysed by MGG staining (A,C). Hoechst 33342 stained nuclei of U1810 and U1285 cells (B,D) were used to observe nuclear condensation/fragmentation. The picture represents results from one out of three independent experiments SCLC cell lines, except U1285 (Joseph et al., 1999) . Processing of the zymogen was observed by Western blot technique in all cell lines expressing pro-caspase-8 (U1285, U1810, and Jurkat) upon STS treatment ( Figure 4A ). However, this processing never preceded the release of cytochrome c, suggesting that this is a secondary event in the caspase cascade induced by STS treatment.
Processing of pro-caspase-9 was also investigated in STS-treated SCLC and NSCLC cell lines by Western blot technique ( Figure 4A ) and its activation was measured by the cleavage of¯uorogenic substrate LEHD-AMC that corresponds to a preferred cleavage site for this protease ( Figure 4B1 ). Analysis of immunoblotting results revealed a marked decline of the proform of caspase-9 in all cell lines treated with STS ( Figure 4A ). This disappearance was con®rmed by densitometric analysis of immunoblots stained with Abs against the reference protein (G3PDH). For unknown reasons we were not able to detect the cleavage product of pro-caspase-9 in STS-treated U1285 and H82 cells with this and two other anticaspase-9 Abs used ( Figure 4A and data not shown). Processed caspases are not necessarily catalytically active since processing and activation are under control of dierent protein factors (Stennicke and Salvesen, 2000) . To con®rm the fact that in STS-treated cells processing of pro-caspase-9 is followed by its activation, cleavage of the¯uorogenic substrate LEHD-AMC was investigated. Basal caspase-9 activity was observed in all lung cancer cell lines tested ( Figure 4B1 and data not shown). This activity was not documented in untreated Jurkat cells. However, in Jurkat as well as in lung cancer cells the activation of caspase-9 was recognized at 6 h after STS treatment, compatible with time of cytochrome c release (Figures 3 and 4B1) .
Activation of the executioner caspases-3 and -7 is observed upon cell treatment with staurosporine
It is well known that both receptor-and non-receptormedicated apoptosis converge to a common pathway where activation of the executioner caspases (caspases-3, -6, and -7) takes place. Processing/activation of procaspases-3 and -7 by Western blot technique was investigated and caspase-3-like activity was measured by DEVD-AMC cleavage in SCLC and NSCLC cells upon STS treatment ( Figure 4A ,B2). Pro-caspase-3 and -7 are present in cells as proteins with molecular weight 32 kDa and 35 kDa, respectively (Zhivotovsky et al., 1999b) . Corresponding bands were detected in all tested untreated lung cancer cells ( Figure 4A ). After treatment with STS the proforms of both executioner caspases showed a marked decline in both types of lung carcinomas ( Figure 4A ). To investigate whether in STS-treated lung cancer cells disappearance of native (A) Untreated (1, 3, 5 and 7) and treated with 1 mM STS (2, 4, 6 and 8) U1285 SCLC (1, 2), H82 SCLC (3, 4), U1810 NSCLC (5, 6), and Jurkat T cells (7, 8) , were analysed using the TUNEL assay as described in Materials and methods. (B) H82 and U1810 cells were treated with 1 mM STS and analysed at 24 h. Distribution of the cells in the G 1 , S, and G 2 /M phases of the cell cycle as well as appearance of sub-diploid fragmented nuclei derived from apoptotic cells were analysed by¯ow cytometry after DNA-staining with propidium iodide. Data shown are representative of multiple independent FACS analyses band in Western blot analysis is related to enzyme activation, cleavage of the¯uorogenic substrate DEVD-AMC was analysed. Both caspases-3 and -7 belong to the family of caspase-3-like enzymes and can cleave this tetrapeptide. A low basal caspase-3-like activity was detected in untreated cells ( Figure 4B2 ). The augmented release of¯uorogenic group (AMC) from the caspase-3-like substrate at 6 h following STS treatment in all cell types con®rmed the activation of executioner caspases documented by the disappearance of pro-caspases-3 and -7 in the Western blot analysis ( Figure 4B2 ).
PARP cleavage occurs in both types of lung cancer cells
One of the biochemical hallmarks of apoptosis is cleavage of PARP induced by caspases-3 and -7 (Tewari et al., 1995; Germain et al., 1999) . Presence of native 116 kDa PARP along with an additional band corresponding to the 89 kDa cleavage product in untreated U1285 and H82 cells were documented ( Figure 5 and data not shown). This spontaneous PARP cleavage was previously described and did correlate with the high level of spontaneous apoptosis in the SCLC cells (Joseph et al., 1999 (Joseph et al., , 2001 . In untreated U1810 and Jurkat cells only the 116 kDa band of PARP was detected ( Figure 5 ). However, 24 h after STS treatment the appearance of the 89 kDa cleavage band in NSCLC and Jurkat cells as well as a signi®cant accumulation in SCLC cells were observed ( Figure 5 ).
Effect of zVAD-fmk on staurosporine-induced caspase activation and PARP cleavage
In order to understand the implication of caspases in mechanism(s) of STS-induced killing of lung cancer cells, the eect of zVAD-fmk, a pan-caspase inhibitor, was investigated. Cells were pre-incubated for 1 h with 20 mM zVAD-fmk and caspase-9 and caspase-3-like activities were analysed by measuring cleavage of LEHD-AMC ( Figure 4B1 ) and DEVD-AMC ( Figure  4B2 )¯uorogenic substrates, respectively. Treatment with aFas was used as a positive control in our experiments. Both aFas-and STS-treatments induced increase in DEVDase activity in U1285, U1810 and Jurkat cells as documented by the release of AMC ( Figure 4B2 ). It is important to note that caspase-3-like activity induced by STS was signi®cantly higher than in cells treated with aFas. Pretreatment with zVAD-fmk strongly inhibited STS-induced caspase-9 activity ( Figure 4B1 ). As a consequence, zVAD-fmk completely inhibited activity of caspase-3-like proteases in all tested cells treated with both STS and aFas ( Figure  4B2 ).
Using Western blot technique cleavage of the nuclear protein PARP was investigated in cells pretreated with zVAD-fmk. Again aFas treatment induced signi®cantly less cleavage of PARP as compared with STS treatment in U1285 SCLC and in Jurkat T cells and, as was previously described, was unable to induce processing of PARP in the U1810 NSCLC cells ( Figure  5A , lane 3). The 89 kDa band corresponding to the cleavage product of PARP appeared in untreated U1285 cells (see explanation above) and was suppressed by zVAD-fmk pretreatment ( Figure 5B , lane 1 vs 2). aFas-induced PARP cleavage, which occurred in U1285 and Jurkat cells, was also totally inhibited by the presence of the pan-caspase inhibitor ( Figure 5B,C lanes 3 vs 4). Pre-treatment with zVAD-fmk did not totally abrogate STS induced-PARP cleavage in all cell lines tested ( Figure 5 , lanes 5 vs 6). However, even if the inhibitory eect of zVAD-fmk on STS-induced PARP cleavage was not absolute, this eect was signi®cant.
zVAD-fmk does not inhibit staurosporine-induced cell death
Since zVAD-fmk inhibited activation of the caspase cascade, one could expect that this broad-spectrum caspase inhibitor might also abolish STS-induced cell death. Incubation of lung cancer cells with zVAD-fmk did not in¯uence their survival. These cells behaved as normal untreated cells. As expected from previously published results (Ekert et al., 1999; Joseph et al., 2000) , zVAD-fmk was able to suppress apoptosis induced by aFas in Jurkat as well as in U1285 SCLC Figure  1B,D) . Altogether these data suggested that STS as compared to aFas treatment induces cell death in both types of lung carcinoma, SCLC and NSCLC, but that Figure 4 Activation of caspases upon staurosporine treatment and its inhibition by zVAD-fmk in SCLC and NSCLC cells. Cells were incubated with 1 mM STS or 250 ng/ml aFas for 24 h, except for aFas and STS-treated Jurkat cells, which were incubated for 6 and 4 h, respectively. (A) Pro-caspases-3, -7, -8 and -9 processing. Cells were harvested and lysed as described in Materials and methods, and protein extracts were analysed by Western blot for the presence of the indicated pro-caspases using antibodies directed against pro-caspases-3, -7, -8, and -9. G3PDH was used as a standard for the equal loading of protein in the lanes. (B) Caspase-9 and caspase-3-like activities. Cells (B1: bar 3; B2: bars 2, 4 and 6) were pretreated for 1 h with the caspase inhibitor zVAD-fmk (20 mM). Caspase-9 activity (B1) and caspase-3-like activity (B2) were determined by the cleavage of the speci®c peptide substrate LEHD-AMC and DEVD-AMC, respectively. The maximum linear rate of AMC release (pmol/min) was estimated by linear regression (r AIF release is detected upon staurosporine treatment of SCLC and NSCLC cells AIF is a novel apoptotic eector protein described recently and de®ned as a caspase-independent mitochondrial death eector (Susin et al., 1999; Daugas et al., 2000; Josa et al., 2001) . In untreated cells AIF is strictly con®ned to mitochondria and upon induction of apoptosis by various agents this protein releases from mitochondria into the cytosol and translocates to the nucleus, where it is involved in large-scale DNA fragmentation and chromatin condensation. Release of AIF from mitochondria in lung carcinoma cells was investigated by confocal immuno¯uorescence microscopy. Detection of AIF using FITC-conjugated antibodies (green¯uorescence) yielded a punctate cytoplasmic staining pattern with some preference for the perinuclear area, as shown by simultaneous PI staining (red¯uorescence) of the nuclei ( Figure 6 , left panels). This pro®le of staining is typical for proteins' mitochondrial localization. Five hours after treatment with 1 mM STS mitochondrial release of AIF in both types of lung carcinoma cells was observed, as documented by the loss of punctate cytoplasmic staining and appearance of more diuse distribution of AIF ( Figure 6 , middle panels). As was mentioned above, in untreated cells AIF (revealed by FITC in green) spares the nucleus (stained by propidium iodide, PI, red) ( Figure 6 , left panels). However, after STS treatment a large portion of AIF was found within the nucleus. This translocation into the nucleus was documented by the appearance of yellow staining corresponding to a colocalization of green (FITC-AIF) and red (PI-nuclei)¯uorescence in confocal microscope ( Figure 6 , middle panels). This nuclear relocalization of AIF appeared to be more pronounced in NSCLC U1810 cells compared with SCLC U1285 cells ( Figure 6 , U1810 vs U1285). The dierence was probably accentuated by the anoikis observed in the STS-treated U1810 cells (Figure 6 , middle panel). To investigate whether translocation of AIF was restricted to the above mentioned cells, experiments using additional NSCLC cell lines (H23 and H157) were performed. Upon treatment with STS AIF was found to translocate in these cells as well (data not shown), suggesting that this is a general phenomenon occurring in all tested NSCLC cell lines. Thus for the ®rst time we found that during apoptosis induced by STS in lung carcinoma cells, AIF is redistributed from mitochondria to the nucleus, which is not a case after girradiation of NSCLC cells ( Figure 6 , right panels) or their treatment with etoposide (data not shown).
Staurosporine induces a drop of mitochondrial membrane potential and superoxide generation in the g-radiation resistant U1810 NSCLC cells
In various experimental models, the loss of DC m followed by the subsequent generation of reactive oxygen species (ROS) resulting from the uncoupling of the respiratory chain appears to be one of the early apoptotic events (Zamzami et al., 1995) . Whereas the translocation of cytochrome c from mitochondria to cytosol does not require a mitochondrial transmembrane depolarization (Martinou and Green, 2001) , the release of AIF from the mitochondrion has been shown to be dependent on the opening of mitochondrial permeability transition pores . In a previous study we have shown that gradiation induces a release of cytochrome c in both types of lung carcinomas, SCLC and NSCLC (Joseph et al., 2001) . However, in spite of this release in both types of lung carcinomas, apoptosis was only documented in the SCLC cells. STS treatment also induced release of cytochrome c in SCLC and NSCLC ( Figure  3 ), but, contrary to g-radiation treatment, this compound induced apoptotic cell death in both types of lung carcinoma cells (Figures 1 and 2) . Therefore, the loss of DC m and generation of ROS in lung cancer cells upon g-radiation and STS treatment were investigated. As shown in Figure 7 , g-irradiation induced DC m disruption measured by the reduction of the uptake of the potential-sensitive dye DiOC 6 (3) in U1285 SCLC cells (increase in the percentage of DiOC 6 (3) l 8 w HE 7 cells). This loss of DC m observed at 24 h after irradiation was followed by an enhanced ROS formation detected by the oxidation of dihydroethidine to the¯uorescent product ethidium (HE + cells). U1810 NSCLC cells after g-irradiation displayed identical to Figure 5 PARP processing upon staurosporine or anti-Fas treatment and its inhibition by zVAD-fmk in SCLC and NSCLC cells. Cells were incubated with 250 ng/ml aFas or 1 mM STS for 24 h, except for aFas and STS-treated Jurkat cells, which were incubated for 6 and 4 h, respectively. Cells were pretreated 1 h with the caspase inhibitor zVAD-fmk (20 mM). Cells were harvested and lysed as described in Materials and methods, and protein extracts were analysed by Western blot for the presence of 116 kDa intact PARP and its 89 kDa cleavage fragment. G3PDH was used as protein loading standard (data not shown) control cells features for these two parameters even at 24 h after treatment. In contrast, STS treatment induced a rapid DC m disruption in both SCLC (U1285) and NSCLC (U1810) cells (increase in the percentage of DiOC 6 (3) l 8 w HE 7 cells), followed by superoxide generation (HE + cells). In U1810 NSCLC cells, STS-treatment, as compared to g-irradiation, induced a rapid drop in DC m , occurring within the ®rst 2 h (data not shown), and at 4 h most of the cells were HE + (Figure 7 ). Similar changes were observed also in H23 and H157 NSCLC cells (data not shown). These mitochondrial events were insensitive to pretreatment of cells with pan-caspase inhibitor zVADfmk (Figure 7 ).
Discussion
Lung cancer is the major cause of cancer deaths in the Western world as well as a growing problem in developing countries (Schottenfeld, 1996) . Lung cancer can be divided into two broad groups: SCLC and NSCLC (Travis et al., 1996) . SCLC is one of the most virulent forms of human cancer and is characterized by early dissemination and a more aggressive clinical evolution as compared to NSCLC. The initial responsiveness of SCLC to anti-cancer treatment is also in contrast with a relative resistance of NSCLC (Owens and Abelo, 1985; Comis et al., 1998) . Taking into consideration that NSCLC accounts for about 75% of bronchogenic carcinomas and their resistance to radiation and drug treatment, this type of tumor remain a priority for public health. The reasons for dierences in sensitivity to treatment of SCLC and NSCLC cells are still not known. It has been suggested that one of the possible explanations might be a dierent propensity of SCLC and NSCLC to undergo apoptosis (Joseph et al., 2000) . Detailed analysis revealed that in NSCLC cells the inhibition of the apoptotic pathway occurs downstream of mitochondrial changes (cytochrome c release) and caspase activation and upstream of nuclear events (Joseph et al., 2001) . Thus, the search for the factor(s) that can avoid the inhibition of the apoptotic process as well as increase the sensitivity of NSCLC cells to treatment may help to improve the therapeutic ecacy of these and other solid tumors.
More than 20 years ago staurosporine was isolated from bacteria and identi®ed as a potent inhibitor of protein kinase C (PKC). Recently the antineoplastic activity of its analog was described, although the role of the enzyme family of PKC in the mechanisms by which these agents interfere with malignant cell growth is still unclear (Gescher, 2000) . Our data show that NSCLC cells, resistant to dierent types of treatment, in fact do undergo apoptosis upon incubation with STS. In NSCLC cells the activation of eector caspases induced by STS in contrast to treatment with gradiation or etoposide is followed by the cleavage of cytosolic and nuclear substrates as well as morphological nuclear changes. This may be interpreted as re¯ecting translocation of active caspase-3 into the nuclei of NSCLC cells after STS treatment. It, however, was important to understand which factor(s) Figure 6 AIF redistribution from mitochondria to nuclei upon staurosporine treatment in SCLC and NSCLC cells. U1285 and U1810 untreated-and 1 mM STS treated-cells were analysed 5 h after treatment. g-Irradiated (8 Gy) cells were analysed 24 h after treatment. Confocal analysis of AIF localization was performed by indirect immuno¯uorescence of AIF using the anti-AIF antibody revealed by an FITC-conjugated anti-rabbit antibody (green¯uorescence). Nuclei were stained with PI (red¯uorescence). The yellow color is the result of an overlay between the green¯uorescence (AIF) and the red one (nucleus) determining the nuclear localization of AIF are required for the killing of NSCLC cells. Since caspases were activated upon STS treatment, inhibitory analysis might help us to understand the exact role, if any, that caspases play in STS-induced killing. Even if the pan-caspase inhibitor zVAD-fmk abrogated the activities of caspases and reduced the processing of PARP, it did not prevent STS-induced cell death. Moreover, neither the overexpression of dominant negative caspase-9 in Jurkat T cells (Stepczynska et al., 2001) nor the use of caspase-3 null MCF-7 cells (Johnson et al., 2000) were able to abolish STS-induced apoptosis. These data suggested that STS treatment, in addition to a caspase-dependent pathway, might also activate a caspase-independent mechanism.
In the past few years, a caspase-independent pathway involving AIF has emerged. As was mentioned above, in untreated cells AIF is located in the intermembrane space of mitochondria and upon induction of apoptosis it is translocated to the nucleus. Recombinant AIF was sucient to induce changes in isolated nuclei speci®c for apoptosis and was able to induce release of cytochrome c from isolated mitochondria. Microinjection of AIF into the cytoplasm of intact cells induced dissipation of the mitochondrial transmembrane potential, condensation of chromatin and exposure of phosphatidylserine. None of these eects were prevented by the pan-caspase inhibitor zVAD-fmk (Susin et al., 1999; Daugas et al., 2000) . Altogether, these data indeed suggested that AIF is a caspase-independent mitochondrial death eector.
Analysis of our results suggested that it is likely that in lung carcinoma cells at least two apoptotic pathways coexist (Figure 8) . The ®rst one, is ecient in SCLC cells and non-ecient in NSCLC cells after treatment with g-radiation and VP-16, and operates via the release of cytochrome c and activation of caspases (Joseph et al., 2001) . The second one, is ecient in both types of cells in response to STS, is independent of caspases and operates via induction of mitochondrial dysfunction followed by the redistribution of AIF from the mitochondria into the nucleus. In the cells, the function of these pathways are presumably not exclusive, rather redundant and/or additive. It appears that some apoptotic stimuli may speci®cally induce one of these pathways, or simultaneously both of them. Thus, it seems that in U1285 SCLC cells, aFas treatment activates only the caspase-dependent pathway and as a result aFas-induced apoptosis is abolished by a low concentration of the zVAD-fmk. However, the same or slightly higher concentrations of this pan-caspase inhibitor were unable to abrogate STS-induced apoptosis in both types of lung carcinomas. These results are compatible with data obtained using other experimental models (Deas et al., 1998; Daugas et al., 2000) . In all cases the pan-caspase inhibitor was able to inhibit caspase activity, but did not prevent the STS-induced mitochondrion-nuclear translocation of AIF and did not rescue cells from death in response to STS.
As was mentioned above, in NSCLC cells STStreatment induced a mitochondrial dysfunction, characterized by a rapid drop of DC m and accumulation of ROS. This loss of MPT preceded the release of AIF and cytochrome c, as well as changes in nuclear morphology. Similar to our experimental model a loss of MPT was recently observed in HeLa cells treated Figure 7 Disruption of the mitochondrial membrane potential and superoxide generation upon treatment with staurosporine or gradiation. Cells were harvested after a 4 h treatment with 1 mM STS or 24 h after g-irradiation (8 Gy). In some experiments cells were pretreated for 1 h with pan-caspase inhibitor zVAD-fmk (20 mM). Cells were analysed as described in Materials and methods for the disruption of the DC m (determined by means of DiOC 6 (3);6axe, FL 1 ) and generation of superoxide anion (determined by HE; y axe, FL 3 ) with STS (Tafani et al., 2001) . Again pan-caspase inhibitor, zVAD-fmk did not inhibit the drop of DC m . Thus, induction of MPT might be an essential step in the killing of cells by STS. The authors found that STS caused the translocation of Bax to the mitochondria, an event that was accompanied by induction of MPT. It is interesting to note that stable transfectants that expressed Akt were resistant to STS treatment and did not develop MPT. In these cells phosphorylation of Bad prevented Bax translocation. These data are consistent with a hypothesis that`the movement of Bax to the mitochondria a requisite gateway to mitochondrial dysfunction and death' (Wei et al., 2001) . This`gate' is usually closed by Bcl-2 and related proteins from the same family (for review see Hengartner, 2000) . Indeed, ectopic expression of antiapoptotic oncogenes, such as bcl-2 and bcr-abl, not only inhibited apoptosis but also preserved the clonogenic potential of the cells (Kluck et al., 1997; Yang et al., 1997; Amarante-Mendes et al., 1998) . Using a large panel of lung carcinoma cell lines we have shown that SCLC cells expressed Bcl-2 at a high level, whereas very low level of this protein was observed in NSCLC cells (Joseph et al., 1999) . Bcl-2 expression did not correlate with the propensity of the cells to undergo apoptosis upon g-radiation, etoposide, or aFas treatment, since the NSCLC cells were cross-resistant to these stimuli. Nevertheless it is interesting to notice that upon STS treatment the release of AIF was more pronounced in U1810 NSCLC cells as compared with SCLC cells. This observation suggests that the level of Bcl-2 in cells may re¯ect their propensity to release mitochondrial apoptogenic factor depending on stimuli. Indeed, the redistribution of AIF has been shown to be prevented by the Bcl-2 protein targeted to mitochondrial membrane (Daugas et al., 2000) . In conclusion, as compared with many of anticancer drugs, STS presumably induces apoptosis by targeting a cytoplasmic regulator(s) of cell death. Although the initial cytosolic target for STS is unknown (it could be à cocktail' of kinases), this compound induces mitochondrial dysfunction, followed by the release of AIF and other mitochondrial proteins. AIF translocates to the nuclei and induces initial chromatin condensation and formation of high molecular weight DNA fragments. Simultaneously, the release of cytochrome c leads to the activation of the apoptosome complex with subsequent production of active caspase-3. While the mechanism of translocation of active caspase-3 into the nuclei is unknown, in NSCLC cells upon treatment with STS this translocation occurs after appearance of AIF within the nuclei (data not shown). Being in the nuclei, active caspase-3 induces cleavage of several proteins, including DNA-PK, PARP and ICAD/DFF45, followed by advanced chromatin condensation and formation of oligonucleosomal DNA fragmentation (Figure 8 ). We believe that in lung carcinomas apparently two cell death pathways (caspase-dependent and caspase-independent) coexist. In SCLC cells both pathways are ecient and their activation is triggerspeci®c. In NSCLC cells upon treatment with conventional drugs, the caspase-dependent pathway is noneective. To kill these cells it is important to target mitochondria, which is followed by the release of AIF and activation of a caspase-independent pathway. To our knowledge, this is the ®rst study demonstrating the possibility to eectively kill non-small lung carcinoma cells, which are resistant to classical anti-cancer therapies. STS or mainly its derivatives, such as 7-hydroxystaurosporine (UCN-01) or N-benzoylstaurosporine (CGP 41251) exhibit antitumor activity in experimental tumor models and are presently in clinical trial (Gescher, 2000) . It would therefore be of interest to know if the clinical eect of these analogues correlates with biochemical changes described above, in particular the release of AIF as well as its and caspase-3 translocation into the nuclei of tumor cells with clinical resistance to conventional cancer treatment.
Materials and methods
Antibodies and reagents
Antibodies against pro-caspase-3 for Western blot (rabbit IgG), active caspase-3 for immuno¯uorescence technique (rabbit IgG), pro-caspase-7 (mouse IgG) all from PharMingen (San Diego, CA, USA), pro-caspase-8 (mouse IgG, gift from Dr PH Krammer, German Cancer Research Center, Heidelberg, Germany), pro-caspase-9 (rabbit IgG, PharMingen), poly(ADP-ribose)polymerase (PARP) (rabbit IgG, Biomol, Plymouth, PA, USA), cytochrome c clone 7H8.2C12 for Western blot (mouse IgG, gift from Dr R Jemmerson, Minneapolis, MN, USA), clone 6H2-B4 for immuno¯uores-cence technique (mouse IgG, PharMingen), AIF (rabbit IgG, produced by Dr G Kroemer's group), G3PDH (rabbit IgG, Trevigen, Gaithersburg, MD, USA) and actin (rabbit IgG, Sigma, St. Louis, MO, USA) were used in this study. Peroxidase conjugated goat anti-rabbit IgG and goat antimouse IgG from Pierce (Rockford, USA) at 1 : 10 000 were used as secondary antibodies. Biotin-conjugated anti-active caspase-3 antibody was revealed by Streptavidin-FITC (PharMingen). ECL was from Amersham (Buckinghamshire, UK). Agonistic anti-Fas monoclonal antibodies (clone CH-11), and staurosporine were purchased from Medical & Biological Laboratories, Ltd. (Nagoya, Japan), and Sigma, respectively. The¯uorogenic peptides DEVD-AMC and LEHD-AMC were obtained from Peptide Institute, Inc. (Osaka, Japan), and the caspase inhibitor zVAD-fmk from Enzyme Systems Products (Dublin, CA, USA).
Cell culture and treatments
Two previously characterized SCLC cell lines, U1285 (Bergh et al., 1982) , and NCI-H82 (ATCC HTB-175), three NSCLC cell lines, U1810 (Bergh et al., 1985) , NCI-H23 (ATCC CRL-5800), NCL-H157 (ATCC CRL-5802) as well as the Jurkat cell line (human T cell leukemia, ATCC TIB 152) were used in this study. U1285 SCLC and U1810 NSCLC cells have been described as expressing pro-caspase-8, whereas NCI-H82 cells were de®cient for this enzyme (Joseph et al., 1999) . Cells were cultured at 378C, 5% CO 2 in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine, penicillin (100 U/ml) and streptomycin (100 mg/ml).
Twenty-four hours after setting in culture dishes with fresh medium cells were treated by adding 1 mM STS or 250 ng/ml aFas antibodies, or by g-radiation (8 Gy, SSD 65 cm, 1.5 Gy/ min) at ambient room temperature. Controls were mock irradiated. The cell permeable caspase inhibitor zVAD-fmk (20 mM) was added 1 h before treatment. The cell density was kept at levels allowing exponential growth.
Western blot analysis
Laemmli's loading buer (100 ml/10 6 cells) was added to harvested cells and samples were boiled for 3 min. Thirty ml of protein extracts were resolved on 7.5, 12 or 15% SDS polyacrylamide gel at 130 V and transblotted onto nitrocellulose membranes (0.2 mm) for 2 h at 100 V. Membranes were blocked overnight in a buer (50 mM Tris, pH 7.5, 500 mM NaCl) supplemented by 1% bovine serum albumin and 5% non-fat milk powder and probed with primary antibody for 1 h, except for pro-caspase-8 (overnight), in blocking solution without milk, followed by the incubation with secondary antibody for 1 h in an identical solution. After repeated washing in PBS bands were visualized by ECL according to the manufacturer's instruction.
Caspase activity assay
The activities of caspase-3-like and caspase-9 enzymes were determined¯uorometrically using DEVD-AMC or LEHD-AMC as substrate, respectively, in a buer containing 100 mM HEPES, 10% sucrose, 0.1% 3-[(3-holamidopropyl) dimethylammonio]-1-propanesulfonic acid, CHAPS, 5 mM DTT, 10 76 % Nonidet P-40, as previously described (Nicholson et al., 1995) .
Cytospins preparation
At dierent time points post-treatment, 15610 4 cells were harvested and cytospins were prepared. Slides were stored at 7208C and thawed for 1 h prior to use for TUNEL-, MGGor Hoechst staining.
TUNEL technique
In situ nuclear DNA fragmentation was measured according to a method based on 3'OH end labeling of DNA breaks with deoxyuridine terminal deoxynucleotidyl transferase (TdT), as previously described (Joseph et al., 2001) . Brie¯y, samples were rehydrated with PBS for 5 min, ®xed in 1% paraformaldehyde (pH 7.4) (Merck, Darmstadt, Germany) for 15 min at 48C, and washed twice with PBS. The TUNEL reaction was carried out by incubating cells for 1 h at 378C in a moist chamber with 1 nmol/ml FITC-12-dUTP (Roche, Germany), 25 mM CoCl 2 , 25 U/ml TdT (Roche) and TdT buer (125 mM Tris-HCl, 1 M potassium cacodylate, 1.25 mg/ml BSA, pH 6.6). After washing in ice-cold PBS for 5 min slides were co-stained with propidium iodide (PI) (Sigma) at 1 mg/ml in PBS, for 10 min at room temperature, washed twice in PBS and mounted with 50% glycerol in PBS. Samples were analysed using an Olympus BX60¯uorescent microscope.
Hoechst DNA staining DNA staining with Hoechst 33342 (Molecular Probes, Oregon, USA) was performed as described (Galli and Fratelli, 1993) . Brie¯y, cells were ®xed by Carnoy solution (methanol : acetic acid, 3 : 1, v/v), stained with Hoechst 33342 (0.1 mg/ml in PBS for 10 min at 378C), washed with water for 5 min, air-dried and mounted with 50% glycerol in PBS. Cells were observed using an Olympus BX60¯uorescent microscope.
Morphological studies
Morphological changes were observed in a light microscope after cell staining with May-GruÈ nwald-Giemsa. Cells displaying chromatin condensation, nuclear disintegration, vacuole formation and membrane blebbing were identi®ed as apoptotic. By contrast, cells with cytoplasmic swelling, membrane disruption and disappearance of nuclear chromatin or distribution of the nuclear chromatin in small illde®ned particles were classi®ed as necrotic.
Immunofluorescence
For confocal microscope analysis, the adherent U1810 cells were grown on coverslides. Cells were washed once in PBS, ®xed in 4% paraformaldehyde and 0.19% picric acid in PBS for 60 min, washed in 1% FCS in PBS for 10 min and permeabilized in the same buer containing 0.1% SDS for 5 min before incubation with rabbit anti-AIF antibody (1 : 250) for 12 h. After three washes in 1% FCS in PBS, cells were incubated with 1 : 1000 FITC-conjugated antirabbit antibody (Fab'2, Sigma) for 1 h and again washed in 1% FCS in PBS. Then nuclei were stained with 0.5 mg/ml PI for 5 min and cells were washed twice in 1% FCS in PBS. Samples were mounted with vectashield (Vector Laboratories, Burlingame, CA, USA) and analysed under Leica TCS MP confocal microscope (Leica Microsystems, Heidelberg, Germany) equipped with an ArKr laser mounted on an inverted Leica DM IFBE microscope with an 6361.32 N NA oil objective.
Cytofluorometric analysis
The distribution of cells in the G 1 , S and G 2 /M cell cycle phases was determined by DNA¯ow-cytometry. Cells were harvested at 1610 6 cells/ml, washed in PBS, ®xed in ice cold 70% ethanol for 30 min and stained with PI (50 mg/ml) in presence of RNase A (0.5 mg/ml). Flow cytometric analysis was carried out using a FACScan¯ow cytometer equipped with CellQuest software (Becton Dickinson, San Jose, CA, USA). Mitochondrial transmembrane potential (DC m ) and superoxide generation were evaluated as described earlier (Zamzami et al., 1995) . Brie¯y, cells (5610 5 /ml) were incubated for 15 min at 378C with 3-3'-dihexyloxacarbocyanine iodide (DIOC 6 (3), 40 nm in PBS; Molecular Probes) and with dihydroethidine (HE, 2 mM in PBS; Molecular Probes). After incubation cells were immediately analysed on a XL cyto¯uorometer (Beckman Coulter, Fullerton, CA, USA).
